Patents by Inventor Henry Luke Danahay

Henry Luke Danahay has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RNAi Inhibition of Alpha-ENaC Expression
    Publication number: 20220235361
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Application
    Filed: April 5, 2022
    Publication date: July 28, 2022
    Inventors: Gino Van Heeke, Emma Hickman, Henry Luke Danahay, Pamela Tan, Anke Geick, Hans-Peter Vornlocher
  • RNAi Inhibition of Alpha-ENaC Expression
    Publication number: 20220112505
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Application
    Filed: December 23, 2021
    Publication date: April 14, 2022
    Inventors: Gino Van Heeke, Emma Hickman, Henry Luke Danahay, Pamela Tan, Anke Geick, Hans-Peter Vornlocher
  • RNAi inhibition of alpha-ENaC expression
    Patent number: 11208662
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: December 28, 2021
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Gino Van Heeke, Emma Hickman, Henry Luke Danahay, Pamela Tan, Anke Geick, Hans-Peter Vornlocher
  • RNAi Inhibition of Alpha-ENaC Expression
    Publication number: 20200157550
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Application
    Filed: January 24, 2020
    Publication date: May 21, 2020
    Inventors: Gino Van Heeke, Emma Hickman, Henry Luke Danahay, Pamela Tan, Anke Geick, JR., Hans-Peter Vornlocher
  • RNAi inhibition of alpha-ENaC expression
    Patent number: 10544418
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Grant
    Filed: January 18, 2018
    Date of Patent: January 28, 2020
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Gino Van Heeke, Emma Hickman, Henry Luke Danahay, Pamela Tan, Anke Geick, Hans-Peter Vornlocher
  • RNAi Inhibition of Alpha-ENaC Expression
    Publication number: 20180148726
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Application
    Filed: January 18, 2018
    Publication date: May 31, 2018
    Inventors: Gino Van Heeke, Emma Hickman, Henry Luke Danahay, Pamela Tan, Anke Geick, Hans-Peter Vornlocher
  • Notch2 binding molecules for treating respiratory diseases
    Patent number: 9944700
    Abstract: The balance and distribution of epithelial cell types is required to maintain tissue homeostasis. In the lung, perturbations of this balance are hallmarks of human respiratory diseases, including goblet cell metaplasia and enhanced mucus secretion in asthma and chronic obstructive pulmonary disease. We found that inflammatory cytokine treatment resulted in a skewing of basal cell differentiation towards a goblet cell fate, culminating in enhanced mucus production. We identified Notch2 as a key node required for cytokine-induced goblet cell metaplasia in vitro and in vivo Inhibition of Notch2 prevents goblet cell metaplasia induced by a broad range of stimuli, which is a hallmark of many respiratory diseases.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: April 17, 2018
    Assignee: NOVARTIS AG
    Inventors: Henry Luke Danahay, Aron Brandon Jaffe
  • RNAi inhibition of alpha-ENaC expression
    Patent number: 9914927
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: March 13, 2018
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Gino Van Heeke, Emma Hickman, Henry Luke Danahay, Pamela Tan, Anke Geick, Hans-Peter Vornlocher
  • RNAi Inhibition of Alpha-ENaC Expression
    Publication number: 20160376599
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Application
    Filed: September 9, 2016
    Publication date: December 29, 2016
    Inventors: Gino Van Heeke, Emma Hickman, Henry Luke Danahay, Pamela Tan, Anke Geick, Hans-Peter Vornlocher
  • RNAi inhibition of alpha-ENaC expression
    Patent number: 9476052
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: October 25, 2016
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Gino Van Heeke, Emma Hickman, Henry Luke Danahay, Pamela Tan, Anke Geick, Hans-Peter Vornlocher
  • NOTCH2 BINDING MOLECULES FOR TREATING RESPIRATORY DISEASES
    Publication number: 20160046710
    Abstract: The balance and distribution of epithelial cell types is required to maintain tissue homeostasis. In the lung, perturbations of this balance are hallmarks of human respiratory diseases, including goblet cell metaplasia and enhanced mucus secretion in asthma and chronic obstructive pulmonary disease. We found that inflammatory cytokine treatment resulted in a skewing of basal cell differentiation towards a goblet cell fate, culminating in enhanced mucus production. We identified Notch2 as a key node required for cytokine-induced goblet cell metaplasia in vitro and in vivo Inhibition of Notch2 prevents goblet cell metaplasia induced by a broad range of stimuli, which is a hallmark of many respiratory diseases.
    Type: Application
    Filed: March 11, 2014
    Publication date: February 18, 2016
    Applicant: NOVARTIS AG
    Inventors: Henry Luke DANAHAY, Aron Brandon JAFFE,
  • RNAi Inhibition of A1pha-ENaC Expression
    Publication number: 20150284726
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Application
    Filed: June 3, 2015
    Publication date: October 8, 2015
    Inventors: Gino VAN HEEKE, Emma HICKMAN, Henry Luke DANAHAY, Pamela TAN, Anke GEICK, Hans-Peter VORNLOCHER
  • RNAi inhibition of alpha-ENaC expression
    Patent number: 9074212
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Grant
    Filed: January 6, 2010
    Date of Patent: July 7, 2015
    Assignee: Arrowhead Research Corporation
    Inventors: Gino Van Heeke, Emma Hickman, Henry Luke Danahay, Pamela Tan, Anke Geick, Hans Peter Vornlocher
  • Organic Compounds
    Publication number: 20120208882
    Abstract: The invention describes novel pharmaceutically acceptable salt forms of camostat, processes for lyophilisation, taste-masked formulations, nebulised formulations and the use of each of the fore-going in the treatment of respiratory diseases, particularly cystic fibrosis and chronic obstructive pulmonary disease (COPD).
    Type: Application
    Filed: February 14, 2012
    Publication date: August 16, 2012
    Inventors: Henry Luke Danahay, Darren Mark LeGrand, David C. Tully, Jennifer Leslie Harris, Silvia Heuerding, Dilraj Singh, Janet Catherine Maas, Juergen Roettele, Jean-Louis Reber, Stéphanie Monnier
  • RNAi inhibition of alpha-ENaC expression
    Patent number: 8168606
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: May 1, 2012
    Assignee: Novartis AG
    Inventors: Gino Van Heeke, Emma Hickman, Henry Luke Danahay, Pamela Tan, Anke Geick, Hans Peter Vornlocher
  • RNAi inhibition of alpha-ENaC expression
    Patent number: 8119612
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: February 21, 2012
    Assignee: Novartis AG
    Inventors: Gino Van Heeke, Emma Hickman, Henry Luke Danahay, Pamela Tan, Anke Geick, Hans Peter Vornlocher
  • RNAi inhibition of alpha-ENaC expression
    Patent number: 7943592
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: May 17, 2011
    Assignee: Novartis AG
    Inventors: Gino Van Heeke, Emma Hickman, Henry Luke Danahay, Pamela Tan, Anke Geick, Hans Peter Vornlocher
  • RNAi inhibition of alpha-ENaC expression
    Patent number: 7939508
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: May 10, 2011
    Assignee: Novartis AG
    Inventors: Gino Van Heeke, Emma Hickman, Henry Luke Danahay, Pamela Tan, Anke Geick, Hans Peter Vornlocher
  • RNAi Inhibition of Alpha-ENaC Expression
    Publication number: 20100216972
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Application
    Filed: April 30, 2010
    Publication date: August 26, 2010
    Inventors: Gino VAN HEEKE, Emma HICKMAN, Henry Luke DANAHAY, Pamela TAN, Anke GEICK, Hans-Peter VORNLOCHER
  • RNAi Inhibition of Alpha-ENaC Expression
    Publication number: 20100216971
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Application
    Filed: April 30, 2010
    Publication date: August 26, 2010
    Inventors: Gino VAN HEEKE, Emma HICKMAN, Henry Luke DANAHAY, Pamela TAN, Anke GEICK, Hans-Peter VORNLOCHER